Abstract 5800
Background
Malignant mesothelioma is an aggressive cancer with poor prognosis and few effective therapies. Due to its derivation from the mesothelium of the lung, immune cells in the tumor microenvironment (TME) may behave differently than in other solid tumors. We describe the combination of two techniques to spatially characterize the tumor-immune profile in mesothelioma.
Methods
47 FFPE mesothelioma tumors were characterized by Definiens’ Immune-Oncology Panel (IOP) and NanoString’s GeoMx™ Digital Spatial Profiling (DSP). Three alternating sequential sections were stained with IOP (CD8/PD-1/FOXP3, CD68/PD-L1/CD3, Granzyme B (GRZMB)). DSP was performed on 12 IOP-derived regions-of-interest (ROIs) on the interleaving slide by a combination of a fluorescent antibodies stain (pan-CK, CD3, CD68) and a panel of 38 UV-photocleavable DNA barcoded antibodies quantified on the nCounter® platform. Gene expression was assessed using NanoString’s PanCancer IO 360™ (IO360) assay.
Results
Cluster analysis based on the IOP revealed 6 distinct immune groups. Two of these had high IOP CD68 density, distinguished by an inhibitory phenotype (PD-L1+) and activated macrophage profile. Subsequent DSP analysis showed that e.g. VISTA, B7-H4 amongst others were higher in the active vs. inhibitory macrophage group. Overall survival (OS) was not associated with density of T cell marker expression measured by IOP/DSP. The IO360 analysis confirmed that and showed tumor-related gene signatures (e.g. proliferation, hypoxia), but not lymphoid-related ones were upregulated in patients with <12 months OS. DSP analysis of VISTA, B2M[BM1] , β-catenin and GRZMB were significantly associated with >12 months OS.
Conclusions
Based on a novel combination of two high-plex spatial analysis techniques, we propose mesothelioma subtypes where macrophages act as immune inhibitory or activated with the latter displaying a possible T-cell excluded phenotype. We also show that deep-profiling of biology within the TME identifies prognostic markers of OS. Thus, we hypothesize that this approach may guide a better understanding and help to develop effective immunotherapies.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Bernard A. Fox.
Funding
Nanostring and Definiens.
Disclosure
T. Herz: Full / Part-time employment: Definiens. S.E. Church: Shareholder / Stockholder / Stock options, Full / Part-time employment: Nanostring. M. Widmaier: Full / Part-time employment: Definiens. A. Budco: Full / Part-time employment: Definiens. D. Medrikova: Full / Part-time employment: Definiens. I. Kanchev: Full / Part-time employment: Definiens. A. Spitzmueller: Full / Part-time employment: Definiens. A. Shaepe: Full / Part-time employment: Definiens. A. White: Shareholder / Stockholder / Stock options, Full / Part-time employment: Nanostring. J. Reeves: Shareholder / Stockholder / Stock options, Full / Part-time employment: Nanostring. A.H. Sullivan: Shareholder / Stockholder / Stock options, Full / Part-time employment: Nanostring. M. Bailey: Shareholder / Stockholder / Stock options, Full / Part-time employment: Nanostring. R. Sanborn: Advisory / Consultancy: CellDex. C. Bifulco: Advisory / Consultancy: Ventana/Roche; Advisory / Consultancy: BMS; Advisory / Consultancy: HalioDx; Advisory / Consultancy, Shareholder / Stockholder / Stock options: PrimeVax. S. Warren: Shareholder / Stockholder / Stock options, Full / Part-time employment: Nanostring. J.M. Beechem: Shareholder / Stockholder / Stock options, Full / Part-time employment: Nanostring. B. Fox: Advisory / Consultancy: Argos; Advisory / Consultancy: AstraZeneca/MedImmune; Advisory / Consultancy, Research support: Bristol-Myers Squibb; Advisory / Consultancy: Bayer; Advisory / Consultancy: CellDex; Advisory / Consultancy: Clearlight; Advisory / Consultancy, Research support: Definiens; Advisory / Consultancy, Research support: Janssen; Advisory / Consultancy, Research support: Macrogenics; Advisory / Consultancy, Research support: Nanostring; Advisory / Consultancy, Research support: OncoSec; Advisory / Consultancy, Research support: PerkinElmer/Akoya; Advisory / Consultancy, Shareholder / Stockholder / Stock options: PrimeVax; Advisory / Consultancy, Research support: Quanterix; Advisory / Consultancy, Research support: Shimadzu; Advisory / Consultancy: Ultivue; Advisory / Consultancy, Research support: Ventana/Roche; Advisory / Consultancy, Research support: Viralytics/Merck; Leadership role, Shareholder / Stockholder / Stock options: UbiVac. All other authors have declared no conflicts of interest.
Resources from the same session
3361 - Providing a nurse-led telephone intervention for patients treated with oral anticancer medication: symptom management and adherence monitoring
Presenter: Etienne Minvielle
Session: Poster Display session 3
Resources:
Abstract
3937 - Chronological evaluation of health-related quality of life and physical symptoms in postoperative pancreatic cancer patients up to 12 months
Presenter: Naoko Sato
Session: Poster Display session 3
Resources:
Abstract
5620 - Understanding the patients’ Experiences of Radiation Therapy: A Qualitative Study on Prostate Cancer Patients
Presenter: Sakarias Johansson
Session: Poster Display session 3
Resources:
Abstract
1792 - Effect of Kegel exercises on prevention of urinary and fecal incontinence in patients with prostate cancer undergoing radiotherapy
Presenter: Aydan Uravylioglu
Session: Poster Display session 3
Resources:
Abstract
2169 - The Meaning of Responsibility – a Secondary Analysis of Patients and Caregivers Calls to an Oncology Emergency Telephone
Presenter: Heidi Jacobsen
Session: Poster Display session 3
Resources:
Abstract
4587 - Cognitive function changes and Associated Factors in Patients Receiving Chemotherapy
Presenter: Elif Dil
Session: Poster Display session 3
Resources:
Abstract
1981 - Prevention of dental complications in patients with multiple myeloma (MM) receiving bisphosphonates treatment
Presenter: CESCA PUIGMARTI
Session: Poster Display session 3
Resources:
Abstract
2725 - Safety profile of oral netupitant/palonosetron in hematopoietic stem cell transplantation recipients.
Presenter: Marina Bosch - Damas
Session: Poster Display session 3
Resources:
Abstract
5112 - Symptomatic and toxicity management of cancer patients using a telephone support model led by the oncology nurse
Presenter: Gemma Simó
Session: Poster Display session 3
Resources:
Abstract
1365 - Symptom cluster of fatigue, sleep disturbance and depression and its impact on quality of life among Chinese breast cancer patients undergoing adjuvant chemotherapy: A cross-sectional study
Presenter: Xiaole HE
Session: Poster Display session 3
Resources:
Abstract